Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Single Dose BI 1358894 on Emotional Processing in MDD
NCT03854578Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bi 1358894 in major depressive disorder (MDD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Mean Blood Oxygenation Level Depend (BOLD) Signal % Change in an Emotional Paradigm, Based on the Emotional Faces From the Warsaw Set of Emotional Facial Expression Pictures (WSEFEP). Started Mar 2019; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03854578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854578.